Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.28 - $2.75 $367,763 - $790,116
287,315 Added 63.25%
741,548 $949,000
Q1 2024

May 15, 2024

SELL
$1.91 - $7.32 $5,397 - $20,686
-2,826 Reduced 0.62%
454,233 $1.31 Million
Q4 2023

Feb 13, 2024

SELL
$4.84 - $8.44 $125,215 - $218,351
-25,871 Reduced 5.36%
457,059 $3.36 Million
Q3 2023

May 14, 2024

BUY
$7.21 - $10.68 $186,529 - $276,302
25,871 Added 5.66%
482,930 $3.71 Million
Q3 2023

Nov 14, 2023

SELL
$7.21 - $10.68 $42,776 - $63,364
-5,933 Reduced 1.21%
482,930 $3.71 Million
Q2 2023

May 14, 2024

BUY
$6.49 - $13.36 $3 Million - $6.18 Million
462,652 Added 1765.11%
488,863 $4.96 Million
Q2 2023

Aug 14, 2023

BUY
$6.49 - $13.36 $3 Million - $6.18 Million
462,652 Added 1765.11%
488,863 $4.96 Million
Q1 2023

May 14, 2024

BUY
$3.78 - $10.38 $60,230 - $165,394
15,934 Added 155.05%
26,211 $254,000
Q1 2023

May 11, 2023

BUY
$3.78 - $10.38 $60,230 - $165,394
15,934 Added 155.05%
26,211 $254,000
Q4 2022

May 14, 2024

SELL
$4.09 - $15.0 $6,343 - $23,265
-1,551 Reduced 13.11%
10,277 $49,000
Q4 2022

Feb 13, 2023

SELL
$4.09 - $15.0 $6,343 - $23,265
-1,551 Reduced 13.11%
10,277 $49,000
Q3 2022

May 14, 2024

SELL
$5.0 - $14.32 $33,780 - $96,745
-6,756 Reduced 36.35%
11,828 $169,000
Q3 2022

Nov 10, 2022

SELL
$5.0 - $14.32 $33,780 - $96,745
-6,756 Reduced 36.35%
11,828 $0
Q2 2022

May 14, 2024

SELL
$3.89 - $7.81 $1.71 Million - $3.42 Million
-438,475 Reduced 95.93%
18,584 $101,000
Q2 2022

Aug 15, 2022

BUY
$3.89 - $7.81 $13,723 - $27,553
3,528 Added 23.43%
18,584 $101,000
Q1 2022

May 16, 2022

BUY
$6.47 - $16.99 $12,254 - $32,179
1,894 Added 14.39%
15,056 $97,000
Q4 2021

Feb 14, 2022

BUY
$16.12 - $31.02 $212,171 - $408,285
13,162 New
13,162 $213,000

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $57.8M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.